Corresponding author.
Author Notes
Copyright and License information
ABSTRACT
Introduction
Dioxins represent a category of enduring environmental contaminants that possess the capability to elicit endocrine disruptions and a spectrum of ailments, most notably encompassing malignancies, immunological impairments, and nervous system impairments. These chemical compounds incite the generation of Reactive Oxygen Species (ROS), consequently instigating cellular toxicity through the activation of the Aryl Hydrocarbon Receptor (AHR). Given the significant noxiousness associated with dioxins, it is imperative to implement decisive actions aimed at mitigating ongoing ambient exposure. In spite of advancements in comprehending the origin and fundamental mechanisms of persistent environmental pollutants, the development of efficacious interventions has remained an elusive endeavor.
Objectives
This investigation focuses on the distinct pharmacological mechanisms inherent in polyphenolic constituents that have been hitherto explored in relation to various dioxin-induced toxicities, both in in vivo and in vitro models.
Materials and Methods
Preclinical studies were identified through systematic searches of PubMed, Embase, and the Cochrane Library, while clinical trials were retrieved from ClinicalTrials.gov and PubMed databases.
Results
Preclinical research unveils the significant efficacy of phytochemicals in mitigating dioxin toxicity. Conversely, clinical findings exhibit a mixed spectrum of outcomes, but hold promise for the use of phytochemicals as adjuncts to conventional therapies for diverse dioxin-induced toxicities. These outcomes suggest that polyphenols may exert substantial influence on disease-related mechanisms such as oxidative stress, inflammation, apoptosis, and gene regulation.
Conclusion
In our assessment, this represents the inaugural comprehensive review encompassing in vitro and in vivo investigations concerning the molecular-level interactions between various environmental contaminants and polyphenols. Furthermore, additional clinical investigations are warranted, with a focus on the appropriate patient populations, identification of relevant toxicity biomarkers, and elucidation of the impact of phytochemicals on these parameters.